EASD-2020 Highlights

EASD-2020 update in brief:- positive concluding notes—- -Higher gathering of beneficial CVD risk factors was correlated with a lower risk of incident CVD in people with T1D, with a dose-response association. In T1D, HbA1c remained the most protective factor versus CVD. Targeting combined risk factors could be more efficacious in inhibiting CVD risk as compared to targeting single risk factors. - An 'eGFR dip' >10% with EMPA was more probably present in T2D patients with more advanced kidney disorder and/or on diuretic treatment. EMPA therapy was safe and showed reduction in CV death, nonetheless of these baseline predictive factors, or an initial 'eGFR dip' >10%. -The current study showed very pronounced impacts of carnitine supplementation on insulin sensitivity, intrahepatic lipid content and concomitant fasting plasma glucose levels in type 2 diabetes patients. It was exhibited that carnitine supplementation showed increase in acetylcarnitine concentration in muscle in the resting state and the capacity to form acetylcarnitine with exercise, which may be fundamental the advantageous impact on insulin sensitivity. It is currently exploring whether certain characteristics, such as baseline acetylcarnitine concentration, are predictive for the strength of the metabolic response to carnitine supplementation. -Icodec is the first once-weekly insulin with similar glucose-lowering impacts and safety profile to once-daily IGlar U100. Insulin icodec has the prospective to enhance therapy acceptance and aid T2D management in patients requiring basal insulin. -Shorter TIR was correlated with the presence of composite microvascular complications, and with retinopathy in specific. A greater SD was associated to peripheral and autonomic neuropathy. TIR was the most vital factor for hospitalization because of hypoglycemia or ketoacidosis.

no answers yet
No answers yet!
To be the first one, click here

Diseases Related to Discussion

Cases that would interest you